Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey
| Autor: | Michael T. Richardson MD, Kristopher Attwood PhD, Gabriella Smith MD, Su-Ying Liang PhD, Katherine LaVigne Mager MD, Krishnansu S. Tewari MD, Robert L. Coleman MD, Daniel S. Kapp PhD, MD, John K. Chan MD, Bradley J. Monk MD |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Cancer Control, Vol 30 (2023) |
| Druh dokumentu: | article |
| ISSN: | 1526-2359 10732748 |
| DOI: | 10.1177/10732748231182795 |
| Popis: | Objectives To evaluate outcomes and cost-effectiveness of targeted therapy sequencing for metastatic and recurrent cervical cancer. Method Models were simulated based on phase II and III trials on bevacizumab (bev) from GOG-240, cemiplimab (cemi) from GOG 3016, pembrolizumab (pembro) from KEYNOTE-826, and tisotumab vedotin (tiso) from GOG 3023. Costs were based on IBM Micromedex RED BOOK™ and company listed costs. Results For [chemo + bev → chemo], total cost was $125,918.04, with median overall survival (mOS) of 21.8 months, and cost-effectiveness ratio (CER) of $119,835.79. For [chemo + bev → cemi], total cost was $187,562.99 with mOS of 28.5 months and CER of $162,039.16. For [chemo + bev + pembro → chemo], total cost was $319,963.78 with mOS 32.9 months and CER of $249,930.10. For [chemo + bev + pembro → tiso], total cost was $455,204.45, with mOS 36.5 months and CER of $320,072.99. Conclusion The combination of immunotherapies and biologics have significantly increased overall survival, but with associated higher costs, primarily related to drug costs. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|